Needham Reiterates Buy on Blueprint Medicines, Maintains $65 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Ami Fadia has reiterated a 'Buy' rating on Blueprint Medicines (NASDAQ:BPMC) and maintained a price target of $65.
August 04, 2023 | 11:12 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst has reiterated a 'Buy' rating on Blueprint Medicines and maintained a price target of $65.
The reiteration of a 'Buy' rating by a Needham analyst and the maintenance of a $65 price target indicates a positive outlook for Blueprint Medicines. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100